FDA Grants Accelerated Approval to Subcutaneous Amivantamab (Rybrevant Faspro) for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

The FDA listed an accelerated approval on November 5, 2026 for amivantamab and hyaluronidase-lpuj (Rybrevant Faspro) in recurrent or metastatic head and neck squamous cell carcinoma. Accelerated approval is contingent on confirmatory trials; trial details were not read beyond the FDA notification listing.